# Optimal Injection Site for Serratus Anterior Plane Block in Reconstructive Breast Surgery

> **NCT03183596** · PHASE3 · WITHDRAWN · sponsor: **University of Alabama at Birmingham**

## Conditions studied

- Pain, Postoperative

## Interventions

- **DRUG:** Bupivacaine
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03183596
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-12
- **Primary completion:** 2020-08
- **Final completion:** 2024-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Principal investigator determination
- **Last updated:** 2018-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03183596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03183596, "Optimal Injection Site for Serratus Anterior Plane Block in Reconstructive Breast Surgery". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03183596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*